S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
NASDAQ:MCRB

Seres Therapeutics - MCRB Stock Forecast, Price & News

$5.57
+0.14 (+2.58%)
(As of 08/18/2022 02:42 PM ET)
Add
Compare
Today's Range
$5.29
$5.57
50-Day Range
$2.70
$5.69
52-Week Range
$2.50
$11.69
Volume
30,706 shs
Average Volume
1.11 million shs
Market Capitalization
$691.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

Seres Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
163.3% Upside
$14.67 Price Target
Short Interest
Healthy
4.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$27.53 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.12) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

182nd out of 1,119 stocks

Pharmaceutical Preparations Industry

74th out of 549 stocks

MCRB stock logo

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics Stock Down 2.9 %

Shares of NASDAQ:MCRB opened at $5.43 on Thursday. The company's 50-day moving average is $3.90 and its 200 day moving average is $5.31. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35. Seres Therapeutics has a fifty-two week low of $2.50 and a fifty-two week high of $11.69.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MCRB shares. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Seres Therapeutics in a report on Wednesday, June 8th. Jefferies Financial Group raised shares of Seres Therapeutics to a "buy" rating in a report on Wednesday, June 8th. Chardan Capital cut their price objective on shares of Seres Therapeutics from $16.00 to $12.00 in a report on Thursday, August 4th. Finally, Piper Sandler cut their price objective on shares of Seres Therapeutics from $32.00 to $7.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd.

Insider Buying and Selling

In related news, major shareholder Health Ltp Fund Ge Nutritional purchased 8,738,243 shares of the business's stock in a transaction that occurred on Tuesday, July 5th. The shares were bought at an average cost of $3.15 per share, with a total value of $27,525,465.45. Following the acquisition, the insider now owns 5,875,711 shares of the company's stock, valued at $18,508,489.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.20% of the stock is owned by insiders.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Daily Biotech/Pharma Pulse: July 7
MCRB,CKPT and RDBX among pre market gainers.
Seres Therapeutics Misses Q1 EPS by 9c
Seres Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings
11/10/2021
Today
8/18/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+163.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-65,580,000.00
Pretax Margin
-75.48%

Debt

Sales & Book Value

Annual Sales
$144.93 million
Book Value
$0.19 per share

Miscellaneous

Free Float
118,861,000
Market Cap
$691.07 million
Optionable
Optionable
Beta
3.15

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 46)
    Pres, CEO & Director
    Comp: $953.1k
  • Mr. David A. Arkowitz M.B.A. (Age 61)
    Exec. VP, CFO & Head of Bus. Devel.
    Comp: $603.33k
  • Dr. Matthew R. Henn Ph.D. (Age 47)
    Exec. VP & Chief Scientific Officer
    Comp: $591.78k
  • Dr. David S. Ege Ph.D. (Age 48)
    Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 67)
    J.D., Chief Legal Officer, Exec. VP & Sec.
  • Ms. Kristin Ainsworth
    Sr. VP of Corp. Communications
  • Mr. Jeff York
    VP of HR
  • Ms. Paula A. Cloghessy SHRM-SCP (Age 50)
    SPHR, Exec. VP & Chief People Officer
  • Dr. Lisa von Moltke M.D. (Age 63)
    Exec. VP & Chief Medical Officer













MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price forecast for 2022?

3 brokerages have issued twelve-month price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they expect the company's stock price to reach $14.67 in the next year. This suggests a possible upside of 170.1% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2022?

Seres Therapeutics' stock was trading at $8.33 on January 1st, 2022. Since then, MCRB shares have decreased by 34.8% and is now trading at $5.43.
View the best growth stocks for 2022 here
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MCRB earnings forecast
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $1.19. The biotechnology company had revenue of $126.73 million for the quarter, compared to analysts' expectations of $7.12 million. Seres Therapeutics had a negative net margin of 75.48% and a negative trailing twelve-month return on equity of 100.32%. During the same period last year, the business earned ($0.36) EPS.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), CVI Holdings LLC (2.19%), State Street Corp (1.18%), Millennium Management LLC (0.88%), Renaissance Technologies LLC (0.95%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Health Ltp Fund Ge Nutritional and Marcus Chapman.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $5.43.

How much money does Seres Therapeutics make?

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $673.71 million and generates $144.93 million in revenue each year. The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Seres Therapeutics have?

The company employs 333 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.